Ondansetron versus dexamethasoneFIGG, W. D.Lancet (British edition). 1991, Vol 338, Num 8772, issn 0140-6736, p. 946Article

The Pharm.D. Investigator in Clinical Pharmacology : Supply and Demand. CommentaryCOHEN, J. L; FIGG, W. D.Clinical pharmacology and therapeutics. 2008, Vol 84, Num 4, issn 0009-9236, 445-447, 526-529 [7 p.]Article

A preliminary risk-benefit assessment of paclitaxelBITTON, R. J; FIGG, W. D; REED, E et al.Drug safety. 1995, Vol 12, Num 3, pp 196-208, issn 0114-5916Article

Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell linesBLAGOSKLONNY, M. V; DIXON, S. C; FIGG, W. D et al.The Journal of urology. 2000, Vol 163, Num 3, pp 1022-1026, issn 0022-5347Article

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependentBAUER, K. S; DIXON, S. C; FIGG, W. D et al.Biochemical pharmacology. 1998, Vol 55, Num 11, pp 1827-1834, issn 0006-2952Article

Intravesical suramin : a novel agent for the treatment of superficial transitional-cell carcinoma of the bladderWALTHER, M. M; FIGG, W. D; LINEHAN, W. M et al.World journal of urology (Print). 1996, Vol 14, pp S8-S11, issn 0724-4983, SUP1Article

Thalidomide, an antiangiogenic agent with clinical activity in cancerNG, S. S. W; BROWN, M; FIGG, W. D et al.Biomedicine & pharmacotherapy. 2002, Vol 56, Num 4, pp 194-199, issn 0753-3322Article

Effect of ABCC2 (MRP2) Transport Function on Erythromycin MetabolismFRANKE, R. M; LANCASTER, C. S; PEER, C. J et al.Clinical pharmacology and therapeutics. 2011, Vol 89, Num 5, pp 693-701, issn 0009-9236, 9 p.Article

Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesisBERGER, A. C; ALEXANDER, H. R; STERN, D et al.Microvascular research (Print). 2000, Vol 60, Num 1, pp 70-80, issn 0026-2862Article

High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasmaRUDEK, M. A; MARCH, C. L; BAUER, K. S et al.Journal of pharmaceutical and biomedical analysis. 2000, Vol 22, Num 6, pp 1003-1014, issn 0731-7085Article

A phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancerBERGAN, R. C; REED, E; STEINBERG, S. M et al.Clinical cancer research. 1999, Vol 5, Num 9, pp 2366-2373, issn 1078-0432Article

Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cellsDIXON, S. C; KRUGER, E. A; BAUER, K. S et al.Cancer chemotherapy and pharmacology. 1999, Vol 43, pp S78-S84, issn 0344-5704, SUPConference Paper

Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer : Simultaneous antiandrogen withdrawal and prior antiandrogen withdrawalDAWSON, N; FIGG, W. D; SAUSVILLE, E et al.Clinical cancer research. 1998, Vol 4, Num 1, pp 37-44, issn 1078-0432Article

Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virusPISCITELLI, S. C; VOGEL, S; FIGG, W. D et al.Pharmacotherapy. 1998, Vol 18, Num 6, pp 1212-1216, issn 0277-0008Article

The pharmacokinetics of TNP-470, a new angiogenesis inhibitorFIGG, W. D; PLUDA, J. M; LUSH, R. M et al.Pharmacotherapy. 1997, Vol 17, Num 1, pp 91-97, issn 0277-0008Article

Treatment approaches for metastatic cancer of the prostate based on recent molecular evidenceMIDDLEMAN, M. N; LUSH, R. M; SARTOR, O et al.Cancer treatment reviews. 1996, Vol 22, Num 2, pp 105-118, issn 0305-7372Article

Pharmacokinetics of ondansetron in patients with hepatic insufficiencyFIGG, W. D; DUKES, G. E; PRITCHARD, J. F et al.Journal of clinical pharmacology. 1996, Vol 36, Num 3, pp 206-215, issn 0091-2700Article

Severe thrombocytopenia in patients treated with suramin : evidence for an immune mechanism in oneTISDALE, J. F; FIGG, W. D; REED, E et al.American journal of hematology. 1996, Vol 51, Num 2, pp 152-157, issn 0361-8609Article

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer : Recommendations from the prostate-specific antigen working groupBUBLEY, G. J; CARDUCCI, M; HUSSAIN, M et al.Journal of clinical oncology. 1999, Vol 17, Num 11, pp 3461-3467, issn 0732-183XArticle

Phase II trial with dose titration of Paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcomaWELLES, L; SAVILLE, M. W; FAJARDO, M. T et al.Journal of clinical oncology. 1998, Vol 16, Num 3, pp 1112-1121, issn 0732-183XArticle

Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human α₁-Acid glycoproteinFUSE, E; TANII, H; FIGG, W. D et al.Cancer research (Baltimore). 1998, Vol 58, Num 15, pp 3248-3253, issn 0008-5472Article

Apoptosis : Its role in the development of malignancies and its potential as a novel therapeutic targetDIXON, S. C; SORIANO, B. J; LUSH, R. M et al.The Annals of pharmacotherapy. 1997, Vol 31, Num 1, pp 76-82, issn 1060-0280Article

Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors : Pharmacokinetics, clinical outcome, and comparison of formulationsKOHN, E. C; FIGG, W. D; SAROSY, G. A et al.Journal of clinical oncology. 1997, Vol 15, Num 5, pp 1985-1993, issn 0732-183XArticle

Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancerBERGAN, R. C; WALLS, R. G; FIGG, W. D et al.Journal of the National Medical Association. 1997, Vol 89, Num 9, pp 622-628, issn 0027-9684Article

A phase I study of pentosan polysulfate sodium in patients with advanced malignanciesLUSH, R. M; FIGG, W. D; PLUDA, J. M et al.Annals of oncology. 1996, Vol 7, Num 9, pp 939-944, issn 0923-7534Article